Compare Mesoblast Limited (MESO) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs MakeMyTrip Ltd — how do they compare? Mesoblast Limited trades at $14.28 (market cap $1.75B), while MakeMyTrip Ltd trades at $44.41 (market cap $4.09B). The key difference: MakeMyTrip Ltd is far larger — about 2.3× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,828,010). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and MakeMyTrip Ltd for 12 Days on average.
| MESO | MMYT | |
|---|---|---|
Market Cap | $1.75B | $4.09B |
Volume | 239,027 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $94.43 |
52-Week Low | $13.19 | $36.30 |
Typical Hold Time | 15 Days | 12 Days |
Enterprise Value | $1.83B | $4.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
MMYT trades at $44.06, up 1.5% with bearish technical signals but strong analyst support. The company reported $978M revenue and $95M net income for 2025, though earnings have been mixed with two recent misses. Valuation metrics show high P/E of 189 but solid gross margins of 73%. Technical indicators show oversold conditions with RSI at 25.31, while institutional sentiment remains positive with 72.7% buy ratings and $77 consensus target.
The stock presents a divergence between technical weakness and fundamental optimism. Upside potential exists from the 75% analyst price target premium and planned Indian listing, but risks include volatile earnings performance, rising debt-to-asset ratio projection to 79.9%, and competitive travel sector pressures. Current levels near support at $42-43 may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
